Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC),European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2021-09-08 , DOI: 10.1002/ejhf.2346
Wouter C Meijers ₁ , Antoni Bayes-Genis ₂ , Alexandre Mebazaa _{3,

4,

5,

6} , Johann Bauersachs ₇ , John G F Cleland ₈ , Andrew J S Coats _{9,

10} , James L Januzzi ₁₁ , Alan S Maisel ₁₂ , Kenneth McDonald ₁₃ , Thomas Mueller ₁₄ , A Mark Richards _{15,

16} , Petar Seferovic _{17,

18} , Christian Mueller ₁₉ , Rudolf A de Boer ₁

Affiliation

Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Heart Institute, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERCV, Barcelona, Spain.
Inserm U942-MASCOT; Université de Paris; Department of Anesthesia and Critical Care, Hôpitaux Saint Louis & Lariboisière; FHU PROMICE, Paris, France.
Université de Paris, Paris, France.
Department of Anesthesia and Critical Care, Hôpitaux Saint Louis & Lariboisière, Paris, France.
FHU PROMICE, Paris, France.
Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Robertson Centre for Biostatistics and Clinical Trials, University of Glasgow; National Heart & Lung Institute, Imperial College London, London, UK.
Monash University, Melbourne, Australia.
University of Warwick, Coventry, UK.
Massachusetts General Hospital, Boston, MA, USA.
University of California, San Diego, CA, USA.
St Vincent's University Hospital, Dublin, Ireland.
Department of Clinical Pathology, Hospital of Bolzano, Bolzano, Italy.
Christchurch Heart Institute, Christchurch, New Zealand.
Cardiovascular Research Institute, National University of Singapore, Singapore.
Faculty of Medicine, Belgrade University, Belgrade, Serbia.
Serbian Academy of Sciences and Arts, Belgarde, Serbia.
University Hospital Basel, University of Basel, Basel, Switzerland.

New biomarkers are being evaluated for their ability to advance the management of patients with heart failure. Despite a large pool of interesting candidate biomarkers, besides natriuretic peptides virtually none have succeeded in being applied into the clinical setting. In this review, we examine the most promising emerging candidates for clinical assessment and management of patients with heart failure. We discuss high-sensitivity cardiac troponins (Tn), procalcitonin, novel kidney markers, soluble suppression of tumorigenicity 2 (sST2), galectin-3, growth differentiation factor-15 (GDF-15), cluster of differentiation 146 (CD146), neprilysin, adrenomedullin (ADM), and also discuss proteomics and genetic-based risk scores. We focused on guidance and assistance with daily clinical care decision-making. For each biomarker, analytical considerations are discussed, as well as performance regarding diagnosis and prognosis. Furthermore, we discuss potential implementation in clinical algorithms and in ongoing clinical trials.

中文翻译：

利钠肽以外的循环心力衰竭生物标志物：来自欧洲心脏病学会 (ESC) 心力衰竭协会 (HFA) 生物标志物研究组的综述

正在评估新的生物标志物促进心力衰竭患者管理的能力。尽管有大量有趣的候选生物标志物，但除了利钠肽之外，几乎没有一个成功地应用于临床环境。在这篇综述中，我们研究了用于心力衰竭患者临床评估和管理的最有希望的新兴候选药物。我们讨论了高敏心肌肌钙蛋白 (Tn)、降钙素原、新型肾脏标志物、可溶性致瘤抑制 2 (sST2)、半乳凝素 3、生长分化因子 15 (GDF-15)、分化簇 146 (CD146)、脑啡肽酶、肾上腺髓质素 (ADM)，还讨论了蛋白质组学和基于遗传的风险评分。我们专注于日常临床护理决策的指导和协助。对于每个生物标志物，讨论了分析注意事项，以及有关诊断和预后的表现。此外，我们讨论了临床算法和正在进行的临床试验中的潜在实施。

更新日期：2021-10-29

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11